Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.

ABSTRACT:

Objective

To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.

Design

Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.

Subjects

Japanese patients aged ≥20 and <50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).

Intervention

Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.

Main outcome measures

Change in E

SUBMITTER: Harada T 

PROVIDER: S-EPMC12905615 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature